Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024.
The first abstract showcased head-to-head data from Charing Cross Hospital, comparing the predictive accuracy of Digistain against Oncotype DX for metastasis-free survival. This significant data forms part of a larger multi-centre study, set to be published early next year.
The second abstract focused on assessing Digistain’s robustness by assessing its performance against variations in tissue fixation time, further demonstrating the reliability of the technology in real-world clinical settings.
These results mark an exciting step forward for Digistain as we continue to bring faster, more cost-effective breast cancer diagnostics to clinicians and patients worldwide.
https://sabcs.org/Call-for-Abstracts-2024
